Phase I Clinical Trial For An H5N1 Bird Flu Vaccine Shows Positive Results

IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine")...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/58Lv1pI8gw4/259340.php

medical rehab sport